{"id":"bortezomib-lenalidomide-low-dose-dex","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"15-25","effect":"Neutropenia"},{"rate":"20-30","effect":"Nausea/vomiting"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Infection"},{"rate":"10-20","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bortezomib is a proteasome inhibitor that blocks NF-κB signaling and induces apoptosis in myeloma cells. Lenalidomide is an immunomodulatory drug (IMiD) that enhances T-cell proliferation and NK cell activity while also having direct anti-proliferative effects. Low-dose dexamethasone provides additional anti-inflammatory and anti-myeloma activity, and the combination has synergistic effects in suppressing multiple myeloma cell growth.","oneSentence":"This combination therapy targets multiple pathways in multiple myeloma by inhibiting proteasome degradation, enhancing immune response, and reducing tumor cell survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:50.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"}]},"trialDetails":[{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT03651128","phase":"PHASE3","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":381},{"nctId":"NCT00581919","phase":"PHASE2","title":"Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2004-02","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT01530594","phase":"PHASE3","title":"Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2009-01","conditions":"Multiple Myeloma","enrollment":440}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bortezomib/Lenalidomide/ Low dose Dex","genericName":"Bortezomib/Lenalidomide/ Low dose Dex","companyName":"King Faisal Specialist Hospital & Research Center","companyId":"king-faisal-specialist-hospital-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy targets multiple pathways in multiple myeloma by inhibiting proteasome degradation, enhancing immune response, and reducing tumor cell survival. Used for Multiple myeloma (newly diagnosed and relapsed/refractory).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}